SIP
ARGS

Stoneridge Investment Partners’s Argos Therapeutics, Inc. ARGS Stock Holding History

Stoneridge Investment Partners’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,182
Closed -$55K – 350
2015
Q4 		$55K Sell
1,182
-169
-13% -$14.3K 0.01% 273
2015
Q3 		$130K Sell
1,351
-15
-1% -$1.78K 0.02% 271
2015
Q2 		$187K Buy
1,366
+402
+42% +$64.2K 0.02% 263
2015
Q1 		$172K Sell
964
-686
-42% -$119K 0.02% 251
2014
Q4 		$330K Buy
1,650
+359
+28% +$64.6K 0.04% 210
2014
Q3 		$260K Hold
1,291
– – 0.04% 210
2014
Q2 		$207K Sell
1,291
-45
-3% -$7.44K 0.03% 211
2014
Q1 		$267K Buy
+1,336
New +$267K 0.05% 167

Other funds holding ARGS

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Ohio Public Employees Retirement System (OPERS)
Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $30.9B AUM 29.72% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Stoneridge Investment Partners's ARGS Position: Q1 2016 in Review

Stoneridge Investment Partners sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2016, closing a stake of 1,182 shares — an estimated $55K sold.

Stoneridge Investment Partners first reported a position in ARGS in Q1 2014 and held it in 8 quarters. The position peaked at $330K in Q4 2014. 21 funds tracked by Wall St. Rank hold ARGS as of Q1 2016.

  • Stoneridge Investment Partners reported no remaining Argos Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Stoneridge Investment Partners sold 1,182 Argos Therapeutics, Inc. shares in Q1 2016, an estimated $55K.
  • Stoneridge Investment Partners first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 8 quarters.
  • Stoneridge Investment Partners's Argos Therapeutics, Inc. position peaked at $330K in Q4 2014.
  • 21 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2016.

Based on Stoneridge Investment Partners's 13F filing for Q1 2016, filed 29 Apr 2016.